INDIANAPOLIS, May 24, 2016 /PRNewswire/ -- In a
presentation to the investment community today, Eli Lilly and
Company (NYSE: LLY) stated it has the potential to launch 20 new
products in the 10 years beginning in 2014 and extending through
2023. In addition, Lilly could launch an average of two new
indications or line extensions for already-approved products per
year during that same time period.
"We're pleased to share with investors the breadth and depth of
the Lilly pipeline, which showcases our progress across our key
therapeutic areas. This includes recent launches as well as a
robust lineup of assets in late-stage development or already under
regulatory review," said John C.
Lechleiter, Ph.D., Lilly's chairman, president and chief
executive officer. "There are no guarantees given the nature of
science and of our business; however, in looking at our recent
launches and current pipeline, we believe we are in the midst of
the most prolific period of new launches in our company's 140-year
history."
Lilly's R&D efforts focus on five therapeutic areas where
the company has assets and capabilities that enable it to compete
successfully. These include four core areas—diabetes, oncology,
immunology and neurodegeneration—and one emerging area—pain.
Building upon a similar investment community meeting in
December 2015 focused on
neurodegeneration – specifically Alzheimer's disease – as well as
animal health, today's presentation highlighted the company's
R&D strategy and progress in diabetes, oncology, immunology and
pain.
"We have improved the productivity and success of our pipeline
through discrete actions aimed at enhancing focus, quality and
speed, and by positioning ourselves as an attractive partner for
external innovation opportunities," said Jan Lundberg, Ph.D., executive vice president of
science and technology and president of Lilly Research
Laboratories. "These improvements have led to the potential for
unprecedented R&D output."
Diabetes
Lilly's long-standing commitment to diabetes
care dates to 1923, when it was the first company to bring insulin
to patients. Today, the company has the broadest range of diabetes
therapies in the industry. Lilly's R&D efforts in diabetes
focus on differentiated therapeutics and delivery devices within
three key areas of unmet need: glucose control, metabolic control
and end-organ protection. The company aims to combine its strong
in-house diabetes R&D capabilities with a comprehensive
external network to deliver continued innovation in this important
area of therapy.
Oncology
Lilly has a long history of leadership in
oncology. The company has a balanced R&D approach across three
key areas of disease modification: tumor cell signaling, tumor
microenvironment and immuno-oncology. This approach allows for
testing of combinations of internally-derived agents to address
tumor heterogeneity and drug resistance. Lilly has a portfolio of
differentiated assets across these approaches, including
Cyramza® (ramucirumab), Portrazza™ (necitumumab),
olaratumab and abemaciclib. Lilly's immuno-oncology portfolio will
have five differentiated molecules in clinical testing by the end
of 2016, and as many as 11 by the end of 2018.
Immunology
With the recent launch of Taltz®
(ixekizumab) and the submission of baricitinib for regulatory
review, Lilly has designated immunology as the company's newest
core therapeutic area. While these assets represent the
foundational first wave of innovation, Lilly has built a robust
emerging pipeline of both internal assets and partnered molecules
focusing on key pathways and interventions in multiple autoimmune
diseases.
Neurodegeneration
Lilly's commitment to Alzheimer's
disease is demonstrated by its more than 25 years of research and
development in the field. As a result of this sustained effort and
deep understanding of the disease, Lilly today has one of the
industry's most comprehensive Alzheimer's portfolios, with seven
molecules already in human testing. The company's Alzheimer's
research includes disease prevention, detection and treatment.
Pain
Pain is an emerging research area for Lilly,
focusing on non-opioid treatment for chronic pain. The two
late-stage innovative medicines currently in development are
galcanezumab (CGRP Ab), being studied for cluster headache and
migraine, and tanezumab, being studied for osteoarthritis pain,
chronic lower back pain and cancer pain in partnership with
Pfizer.
A live audio webcast of today's presentation is available on the
"Webcasts & Presentations" section of Lilly's investor website
at http://investor.lilly.com/events.cfm. A replay will be available
for approximately 90 days.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
newsroom.lilly.com/social-channels. F-LLY
This press release contains management's current intentions
and expectations for the future, all of which are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements include all statements that do not
relate solely to historical or current facts, and can generally be
identified by the use of words such as "may," "will," "estimate,"
"project," "intend," "expect," "believe," "target," "anticipate,"
"plan," and similar expressions. Actual results may differ
materially due to various factors. There are significant risks and
uncertainties in pharmaceutical research and development.
Among other things, there can be no guarantees that
pipeline products will succeed in clinical testing, will receive
the necessary clinical and manufacturing regulatory approvals or
will prove to be commercially successful. The company's results may
also be affected by such factors as the timing of anticipated
regulatory approvals and launches of new products; market uptake of
recently launched products; competitive developments affecting
current products; the expiration of intellectual property
protection for certain of the company's products; the company's
ability to protect and enforce patents and other
intellectual property; the impact of governmental actions regarding
pricing, importation, and reimbursement for pharmaceuticals,
including U.S. health care reform; regulatory compliance problems
or government investigations; regulatory actions regarding
currently marketed products; unexpected safety or efficacy concerns
associated with the company's products; issues with product supply
stemming from manufacturing difficulties or disruptions; regulatory
changes or other developments; changes in patent law or regulations
related to data-package exclusivity; litigation involving current
or future products; the extent to which third-party indemnification
obligations relating to product liability litigation and similar
matters will be performed; unauthorized disclosure of trade secrets
or other confidential data stored in the company's information
systems and networks; changes in tax law and regulations; changes
in inflation, interest rates, and foreign currency exchange rates;
asset impairments and restructuring charges; changes in accounting
standards promulgated by the Financial Accounting Standards Board
and the U.S. Securities and Exchange Commission (SEC); acquisitions
and business development transactions and related
integration considerations; and the impact of exchange rates and
global macroeconomic conditions. For further discussion of
these and other risks and uncertainties, see Lilly's most recent
Form 10-K and Form 10-Q filings with the United States Securities
and Exchange Commission. Except as required by law, Lilly
undertakes no duty to update forward-looking statements to reflect
events after the date of this release.
Refer
to:
|
Molly McCully;
mccully_molly@lilly.com; 317-478-5423 (Media)
|
|
Philip Johnson;
johnson_philip_l@lilly.com; 317-655-6874 (Investors)
|
Logo -
http://photos.prnewswire.com/prnh/20031219/LLYLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lilly-details-robust-rd-pipeline-to-investment-community-300273485.html
SOURCE Eli Lilly and Company